ボディコントゥアリング治療市場 – 2029年までの世界予測

Report Overview

The global body contouring treatments market is expected to reach USD 2.58  billion by 2029 from USD 1.46 billion in 2024, at a CAGR of 10.0% from 2024 to 2029.

世界のボディコントゥアリング治療市場は、2024 年の 14 億 6000 万米ドルから 2029 年までに 25 億 8000 万米ドルに達し、2024 年から 2029 年まで 10.0% の CAGR で成長すると予想されています。

Increase in acceptance of aesthetic procedures, coupled with personalized and flexible financing plans has increased the demand for these products. Growing interest in anti-aging procedures are more prevalent in aging population. Body contouring procedures helps to reshape  and improvesconfidence. Moreover,increased benefits of minimally invasive and non-invasive body contouring procedures have driven demand for body contouring treatments market.

パーソナライズされた柔軟な資金計画と相まって、審美的な手順の受け入れの増加により、これらの製品の需要が増加しています。高齢化社会では、アンチエイジングへの関心がさらに高まっています。体の輪郭を整える処置は、形を整え、自信を高めるのに役立ちます。さらに、低侵襲性および非侵襲性の身体輪郭形成処置の利点の増加により、身体輪郭形成治療市場の需要が高まっています。

“The non-invasive technologies segment of technology segment held the largest share of the market in 2023”

The body contouring treatments market is segmented based on technology into invasive technologies and non-invasive technologies. The non-invasive technologies accounted for a major share in 2023. Increase in technological innovations, rise in advertisement, and the rising adoption of devices due to less incisions is anticipated to fuel the growth of the segment. Treatments for non-invasive body contouring that involve radiofrequency, ultrasound, cryolipolysis (freezing fat), and laser-based techniques have significantly improved in tems of safety and effectiveness. These technologies have a wide range of benefits, which contribute to the non-invasive treatment popularity among individuals.

“The non-surgical fat reduction segment of application segment held the largest share of the market in 2023”

The body contouring treatments market can be segmented  based on application into abdominoplasty, liposuction, non-invasive fat reduction, cellulite treatment, and other applications. Increasing number of beauty centers and rising adoption mainly due to improved  accuracy and better outcomes drives the market. The non-surgical fat reduction treatments are gaining popularity across all patient types and ages. Hence, broader acceptance for treatment procedures due to innovative technologies supports the surge in demand that further drives the growth for  the non-surgical fat reduction segment.

“The female patients segment for patient type segment to hold the largest market share in 2023”.

Based on patient type , the body contouring treatments market is segmented into female patients and male patients. Female patients is the major segment, accounting for the largest body contouring treatments market share in 2023. The increase in awareness about non-invasive body contouring procedures, rise in post-pregnancy body reconstruction  procedures, increase in influencer endorsements, and social media promotion supports the growth of the segment.

“The aesthetic clinics segment for the end user segment is projected to register a significant CAGR during the forecast period.”

The body contouring treatments market is segmented by end-users into hospitals, aesthetic clinics, and medical spas & beauty centers. The hospitals accounted for a major end-user market share in 2023. The increase in spending on body shaping procedures and rise in medical tourism, and rising disposable income per capita is anticipated to propel the segment growth. Furthermore, rising adoption of new and improved devices in the hopsitals is expected to support the growth of this segment.

“The market in the Asia Pacific region is expected to witness the highest growth during the forecast period.”

The north america region accounted for major share in 2023. Asia pacific region to grow at the highest CAGR in body contouring treatments market. Healthcare infrastructure and service investments, especially in the emerging economies, are fostering the development of medical aesthetics, which leads to growing demand for body contouring. In this regard, market leaders have increased their efforts to strengthen their presence in the Asia Pacific market to meet the ever-growing requirement for body contouring treatment. The availability and accessibility of the service in this market have also been enhanced by the increasing presence of aesthetic clinics, particularly in the APAC region.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1–30%, Tier 2–42%, and Tier 3– 28%
• By Designation: Director-level–10%, C-level–14%, and Others–76%
• By Region: North America–40%, Europe–30%, Asia Pacific–22%, Latin America–6%, and RoW- 10%

The prominent players in the body contouring treatments market are as AbbVie Inc. (US), InMode Ltd. (Israel), Bausch Health Companies Inc. (Canada), Cynosure Lutronic (US), Venus Concept (Canada), EL.EN.S.P.A (Italy), Sisram Medical Ltd. (Israel), BTL Industries(UK), Sharplight Technologies Inc. (Canada), Sciton Inc. (US), Candela Corporation (US), Fotona (Solvenia )

The study includes as in-depth competitive analysis of these key players in the authentication and brand protection market, with their company profiles recent developments,and key market stratergies

Research  Coverage

This report studies the body contouring treatments market based on technology, application, patient type, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall body contouring treatments market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

• Analysis of key drivers (Growing adoption for minimally invasive and non-invasive body contouring procedure, increasing demand for aesthetic treatments among men, rising adoption of new and innovative body contouring technologies , broad acceptance of aesthetic procedure and growing attention on appearance and body image), restraints (high cost of treatment and inadequate reimbursement policies), opportunities (growth potential in emerging economies), and challenges (social and cultural barrriers in emerging economies, stringent regulatory compliance and safety standards) influencing the growth of the body contouring treatments market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the body contouring treatments market
• Market Development: Comprehensive information about lucrative markets–the report analyses the body contouring treatments market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the body contouring treatments market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players, such as AbbVie Inc. (US), Inmode Ltd. (Israel), Bausch Health Companies Inc. (Canada), Cynosure Lutronic (US), Sisram Medical Ltd (Israel)

Table of Contents

1               INTRODUCTION              26

1.1           STUDY OBJECTIVES       26

1.2           MARKET DEFINITION   26

1.3           INCLUSIONS AND EXCLUSIONS 27

1.4           STUDY SCOPE   28

1.4.1        MARKETS COVERED       28

1.4.2        YEARS CONSIDERED      29

1.4.3        CURRENCY CONSIDERED            29

1.5           STAKEHOLDERS               29

1.6           IMPACT OF AI/GEN AI   29

2               RESEARCH METHODOLOGY       30

2.1           RESEARCH DATA              30

2.1.1        SECONDARY DATA          30

2.1.1.1    Key sources for secondary research   30

2.1.2        PRIMARY DATA 31

2.1.2.1    Key primary sources             32

2.1.2.2    Key industry insights           33

2.1.2.3    Breakdown of primary interviews      33

2.2           MARKET SIZE ESTIMATION         34

2.2.1        BOTTOM-UP APPROACH              35

2.2.1.1    Company revenue estimation approach            36

2.2.1.2    Customer-based market estimation   37

2.2.1.3    Growth forecast approach   38

2.2.1.4    CAGR projections                 38

2.3           DATA TRIANGULATION                38

2.4           MARKET SHARE ANALYSIS           39

2.5           RESEARCH ASSUMPTIONS           40

2.5.1        PARAMETRIC ASSUMPTIONS     40

2.5.2        GROWTH RATE ASSUMPTIONS 40

2.6           RESEARCH LIMITATIONS             41

2.7           RISK ASSESSMENT           41

3               EXECUTIVE SUMMARY  42

4               PREMIUM INSIGHTS       46

4.1           BODY CONTOURING TREATMENTS MARKET OVERVIEW          46

4.2           NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY        47

4.3           ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY END USER 47

4.4           EUROPE: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION             48

4.5           GEOGRAPHIC SNAPSHOT OF BODY CONTOURING TREATMENTS MARKET 49

5               MARKET OVERVIEW       50

5.1           INTRODUCTION              50

5.2           MARKET DYNAMICS       50

5.2.1        DRIVERS               51

5.2.1.1    Growing adoption of minimally invasive and non-invasive body contouring procedures         51

5.2.1.2    Increasing demand for aesthetic treatments among men                 52

5.2.1.3    Rising adoption of new and innovative body contouring technologies           53

5.2.1.4    Widespread social media influence and cultural changes                 55

5.2.2        RESTRAINTS      56

5.2.2.1    High cost of treatment and inadequate reimbursement policies                 56

5.2.3        OPPORTUNITIES              56

5.2.3.1    Growth potential in emerging economies         56

5.2.4        CHALLENGES    59

5.2.4.1    Social and cultural barriers 59

5.2.4.2    Stringent regulatory compliance and safety standards   59

5.3           VALUE CHAIN ANALYSIS               60

5.3.1        RESEARCH & PRODUCT DEVELOPMENT               61

5.3.2        RAW MATERIAL PROCUREMENT AND MANUFACTURING          61

5.3.3        DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES             61

5.4           SUPPLY CHAIN ANALYSIS             62

5.4.1        MANUFACTURERS           62

5.4.1.1    Prominent companies          62

5.4.1.2    Small and medium-sized enterprises 62

5.4.2        END USERS         62

5.5           ECOSYSTEM ANALYSIS  63

5.6           REGULATORY ANALYSIS               64

5.6.1        REGULATORY LANDSCAPE         64

5.6.1.1    North America      64

5.6.1.1.1 US           64

5.6.1.1.2 Canada   67

5.6.1.2    Europe   68

5.6.1.3    Asia Pacific            71

5.6.1.3.1 Japan      71

5.6.1.3.2 China      71

5.6.1.3.3 India       73

5.6.1.4    Latin America       73

5.6.1.4.1 Brazil      73

5.6.2        REGULATORY APPROVALS          74

5.6.3        KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS  74

5.7           REIMBURSEMENT SCENARIO ANALYSIS                 77

5.8           INVESTMENT AND FUNDING SCENARIO               78

5.9           PRICING ANALYSIS          79

5.9.1        AVERAGE SELLING PRICE OF KEY PLAYERS, BY TECHNOLOGY  80

5.9.2        AVERAGE SELLING PRICE OF BODY CONTOURING DEVICES, BY REGION     81

5.10         TRADE ANALYSIS             82

5.10.1      IMPORT DATA  83

5.10.2      EXPORT DATA  84

5.11         PATENT ANALYSIS          85

5.12         PORTER’S FIVE FORCES ANALYSIS           87

5.12.1      THREAT OF NEW ENTRANTS      88

5.12.2      THREAT OF SUBSTITUTES          88

5.12.3      BARGAINING POWER OF SUPPLIERS       88

5.12.4      BARGAINING POWER OF BUYERS             88

5.12.5      INTENSITY OF COMPETITIVE RIVALRY 88

5.13         KEY STAKEHOLDERS AND BUYING CRITERIA     89

5.13.1      KEY STAKEHOLDERS IN BUYING PROCESS           89

5.13.2      KEY BUYING CRITERIA  90

5.14         KEY CONFERENCES AND EVENTS, 2025–2026        91

5.15         CASE STUDY ANALYSIS 93

5.15.1      IMPROVED FAT REDUCTION PROCEDURES USING LARGER APPLICATOR    93

5.15.2      ENHANCED SUPPLY CHAIN AND OPERATIONAL EFFICIENCY WITH HIGHER RESEARCH & DEVELOPMENT                 93

5.16         TECHNOLOGY ANALYSIS             94

5.16.1      KEY TECHNOLOGIES     94

5.16.1.1  Thermal technologies          94

5.16.1.2  Non-thermal technologies  95

5.16.2      COMPLEMENTARY TECHNOLOGIES       95

5.16.2.1  Skin cooling systems            95

5.16.3      ADJACENT TECHNOLOGIES       95

5.16.3.1  Treatment planning software              95

5.17         TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            96

5.18         UNMET NEEDS 97

5.19         IMPACT OF AI/GEN AI ON BODY CONTOURING TREATMENTS MARKET 98

5.19.1      KEY USE CASES 99

6               BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY  100

6.1           INTRODUCTION              101

6.2           INVASIVE TECHNOLOGIES          101

6.2.1        INVASIVE RADIOFREQUENCY TECHNOLOGY     102

6.2.1.1    Growing inclination toward skin tightening to propel market                 102

6.2.2        INVASIVE LASER TECHNOLOGY                103

6.2.2.1    Higher advantages compared to traditional techniques to speed up growth               103

6.2.3        INVASIVE ULTRASOUND TECHNOLOGY               104

6.2.3.1    Targeted fat reduction and minimal discomfort to augment growth    104

6.3           NON-INVASIVE TECHNOLOGIES               105

6.3.1        NON-INVASIVE RADIOFREQUENCY TECHNOLOGY                 107

6.3.1.1    Rising use of cellulite treatment, fat reduction, and skin tightening to drive market  107

6.3.2        NON-INVASIVE LASER TECHNOLOGY    108

6.3.2.1    Growing adoption in hospitals and aesthetic clinics to fuel market                 108

6.3.3        NON-INVASIVE ULTRASOUND TECHNOLOGY   108

6.3.3.1    Need for precise temperature management control to accelerate growth    108

6.3.4        CRYOLIPOLYSIS TECHNOLOGY 109

6.3.4.1    Low risk and minimal side effects to facilitate growth    109

6.3.5        OTHER NON-INVASIVE TECHNOLOGIES               110

7               BODY CONTOURING TREATMENTS MARKET, BY GENDER               112

7.1           INTRODUCTION              113

7.2           FEMALE PATIENTS          113

7.2.1        GROWING USE OF BODY CONTOURING TO ADDRESS POST-SURGICAL CHANGES TO BOOST MARKET                113

7.3           MALE PATIENTS               115

7.3.1        INCREASING SHIFT IN SOCIAL AND AESTHETIC STANDARDS TO EXPEDITE GROWTH     115

8               BODY CONTOURING TREATMENTS MARKET, BY APPLICATION   117

8.1           INTRODUCTION              118

8.2           NON-SURGICAL FAT REDUCTION            118

8.2.1        GROWING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES TO FUEL MARKET              118

8.3           CELLULITE REDUCTION              120

8.3.1        RISING OBESITY RATES TO SUPPORT MARKET GROWTH             120

8.4           LIPOSUCTION   120

8.4.1        GROWING DEMAND FOR COSMETIC ENHANCEMENT WITH SHORTER RECOVERY TIMES TO DRIVE MARKET  120

8.5           ABDOMINOPLASTY        121

8.5.1        INCREASING DESIRE FOR AESTHETIC IMPROVEMENTS TO PROMOTE GROWTH               121

8.6           OTHER APPLICATIONS 122

9               BODY CONTOURING TREATMENTS MARKET, BY END USER     124

9.1           INTRODUCTION              125

9.2           HOSPITALS         125

9.2.1        BOOMING MEDICAL TOURISM TO CONTRIBUTE TO MARKET GROWTH          125

9.3           AESTHETIC CLINICS       126

9.3.1        GROWING ESTABLISHMENT OF SPECIALTY CLINICS TO DRIVE MARKET 126

9.4           MEDICAL SPAS & BEAUTY CENTERS        127

9.4.1        RISING FOCUS ON BODY APPEARANCE TO AID GROWTH             127

10            BODY CONTOURING TREATMENTS MARKET, BY REGION                129

10.1         INTRODUCTION              130

10.2         NORTH AMERICA             130

10.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 135

10.2.2      US           136

10.2.2.1  Growing public acceptance of body contouring procedures to drive market          136

10.2.3      CANADA               138

10.2.3.1  Rising inclination toward reducing signs of aging to aid growth                 138

10.3         EUROPE               140

10.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      144

10.3.2      GERMANY           145

10.3.2.1  Increasing volume of aesthetic procedures to drive market                 145

10.3.3      FRANCE                147

10.3.3.1  Increasing demand for age-related aesthetic treatments to spur growth    147

10.3.4      UK          149

10.3.4.1  Rising focus of men on body aesthetics to encourage growth                 149

10.3.5      ITALY    151

10.3.5.1  Gowing adoption of surgical procedures among young females to boost market          151

10.3.6      SPAIN    153

10.3.6.1  Growing availability of high-quality and effective products to fuel market    153

10.3.7      REST OF EUROPE             155

10.4         ASIA PACIFIC     157

10.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 161

10.4.2      JAPAN   162

10.4.2.1  Presence of medical aesthetic associations to spur growth                 162

10.4.3      CHINA  165

10.4.3.1  Increased availability of cosmetic surgery apps and online services to support growth 165

10.4.4      INDIA    167

10.4.4.1  Increasing disposable income to contribute to market growth                 167

10.4.5      AUSTRALIA         169

10.4.5.1  Favorable government initiatives to promote growth     169

10.4.6      SOUTH KOREA  171

10.4.6.1  Rising influx of foreign patients to facilitate growth       171

10.4.7      REST OF ASIA PACIFIC   173

10.5         LATIN AMERICA                175

10.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 178

10.5.2      BRAZIL 179

10.5.2.1  Heightened awareness regarding body contouring enhancements to stimulate growth               179

10.5.3      MEXICO                181

10.5.3.1  Increase in patient inflow from US to sustain growth     181

10.5.4      REST OF LATIN AMERICA             183

10.6         MIDDLE EAST & AFRICA                185

10.6.1      GROWING AVAILABILITY OF HIGH-QUALITY TREATMENTS TO DRIVE MARKET            185

10.6.2      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 189

11            COMPETITIVE LANDSCAPE         191

11.1         OVERVIEW          191

11.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            191

11.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BODY CONTOURING TREATMENTS MARKET     191

11.3         REVENUE ANALYSIS, 2019−2023                 194

11.4         MARKET SHARE ANALYSIS, 2023                 195

11.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 197

11.5.1      STARS   197

11.5.2      EMERGING LEADERS     197

11.5.3      PERVASIVE PLAYERS      197

11.5.4      PARTICIPANTS 197

11.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2023         199

11.5.5.1  Company footprint               199

11.5.5.2  Technology footprint           200

11.5.5.3  Gender footprint  201

11.5.5.4  Application footprint            202

11.5.5.5  End-user footprint                203

11.5.5.6  Region footprint   204

11.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        205

11.6.1      PROGRESSIVE COMPANIES         205

11.6.2      RESPONSIVE COMPANIES            205

11.6.3      DYNAMIC COMPANIES  205

11.6.4      STARTING BLOCKS         205

11.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023                 207

11.7         COMPANY VALUATION AND FINANCIAL METRICS                 209

11.7.1      COMPANY VALUATION 209

11.7.2      FINANCIAL METRICS      209

11.8         BRAND/PRODUCT COMPARISON             210

11.9         COMPETITIVE SCENARIO             210

11.9.1      PRODUCT LAUNCHES AND APPROVALS               210

11.9.2      DEALS  213

11.9.3      EXPANSIONS     214

12            COMPANY PROFILES      215

12.1         KEY PLAYERS     215

12.1.1      ABBVIE INC.       215

12.1.1.1  Business overview 215

12.1.1.2  Products offered   216

12.1.1.3  Recent developments           217

12.1.1.3.1                Product launches and approvals         217

12.1.1.4  MnM view              217

12.1.1.4.1                Key strengths        217

12.1.1.4.2                Strategic choices   217

12.1.1.4.3                Weaknesses and competitive threats 217

12.1.2      INMODE LTD.   218

12.1.2.1  Business overview 218

12.1.2.2  Products offered   219

12.1.2.3  Recent developments           220

12.1.2.3.1                Product launches and approvals         220

12.1.2.3.2                Deals      221

12.1.2.4  MnM view              221

12.1.2.4.1                Key strengths        221

12.1.2.4.2                Strategic choices   221

12.1.2.4.3                Weaknesses and competitive threats 221

12.1.3      BAUSCH HEALTH COMPANIES INC.         222

12.1.3.1  Business overview 222

12.1.3.2  Products offered   223

12.1.3.3  Recent developments           224

12.1.3.3.1                Product launches and approvals         224

12.1.3.4  MnM view              224

12.1.3.4.1                Key strengths        224

12.1.3.4.2                Strategic choices   224

12.1.3.4.3                Weaknesses and competitive threats 224

12.1.4      CYNOSURE LUTRONIC  225

12.1.4.1  Business overview 225

12.1.4.2  Products offered   225

12.1.4.3  Recent developments           226

12.1.4.3.1                Deals      226

12.1.4.4  MnM view              226

12.1.4.4.1                Key strengths        226

12.1.4.4.2                Strategic choices   226

12.1.4.4.3                Weaknesses and competitive threats 226

12.1.5      SISRAM MEDICAL LTD   227

12.1.5.1  Business overview 227

12.1.5.2  Products offered   228

12.1.5.3  Recent developments           229

12.1.5.3.1                Product launches and approvals         229

12.1.5.3.2                Deals      229

12.1.5.3.3                Expansions             230

12.1.5.4  MnM view              230

12.1.5.4.1                Key strengths        230

12.1.5.4.2                Strategic choices   230

12.1.5.4.3                Weaknesses and competitive threats 230

12.1.6      CUTERA, INC.    231

12.1.6.1  Business overview 231

12.1.6.2  Products offered   232

12.1.6.3  Recent developments           233

12.1.6.3.1                Product launches and approvals         233

12.1.7      EL.EN. S.P.A.       234

12.1.7.1  Business overview 234

12.1.7.2  Products offered   235

12.1.7.2.1                Product launches and approvals         236

12.1.8      VENUS CONCEPT             237

12.1.8.1  Business overview 237

12.1.8.2  Products offered   238

12.1.8.3  Recent developments           239

12.1.8.3.1                Product launches and approvals         239

12.1.8.3.2                Deals      240

12.1.9      SHARPLIGHT TECHNOLOGIES INC.         241

12.1.9.1  Business overview 241

12.1.9.2  Products offered   241

12.1.9.3  Recent developments           242

12.1.9.3.1                Product launches and approvals         242

12.1.10   SCITON                 243

12.1.10.1                 Business overview 243

12.1.10.2                 Products offered   243

12.1.10.3                 Recent developments           243

12.1.10.3.1             Product launches and approvals         243

12.1.11   CANDELA CORPORATION            244

12.1.11.1                 Business overview 244

12.1.11.2                 Products offered   244

12.1.11.3                 Recent developments           244

12.1.11.3.1             Deals      244

12.1.12   BTL INDUSTRIES              245

12.1.12.1                 Business overview 245

12.1.12.2                 Products offered   245

12.1.12.3                 Recent developments           246

12.1.12.3.1             Product launches and approvals         246

12.1.12.3.2             Deals      246

12.1.13   FOTONA              247

12.1.13.1                 Business overview 247

12.1.13.2                 Products offered   247

12.1.13.3                 Recent developments           248

12.1.13.3.1             Product launches and approvals         248

12.1.14   GZ MTS ELECTRONICS CO., LTD.              249

12.1.14.1                 Business overview 249

12.1.14.2                 Products offered   249

12.1.15   ROHRER AESTHETICS, INC.         252

12.1.15.1                 Business overview 252

12.1.15.2                 Products offered   252

12.1.15.3                 Recent developments           253

12.1.15.3.1             Product launches and approvals         253

12.1.15.3.2             Deals      253

12.2         OTHER PLAYERS              254

12.2.1      GBS INTERNATIONAL HOLDING LTD.   254

12.2.2      SINCLAIR             255

12.2.3      THERMI                256

12.2.4      YOLO MEDICAL INC.      256

12.2.5      DOMINION AESTHETIC TECHNOLOGIES, INC.   257

12.2.6      ZIMMER MEDIZIN SYSTEME GMBH          258

12.2.7      ERCHONIA CORPORATION         259

12.2.8      CLASSYS INC.     260

12.2.9      WON TECH CO., LTD.    261

12.2.10   CELLSOUND AESTHETICS           262

13            APPENDIX           263

13.1         DISCUSSION GUIDE        263

13.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                267

13.3         CUSTOMIZATION OPTIONS        269

13.4         RELATED REPORTS         269

13.5         AUTHOR DETAILS           270

LIST OF TABLES

TABLE 1                BODY CONTOURING TREATMENTS MARKET: INCLUSIONS AND EXCLUSIONS 27

TABLE 2                SURGICAL PROCEDURES PERFORMED ON MALE PATIENTS, 2021–2023          52

TABLE 3                NON-SURGICAL PROCEDURES PERFORMED ON MALE PATIENTS, 2021–2023          52

TABLE 4                NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023

(US, GERMANY, FRANCE, GREECE)           53

TABLE 5                NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023

(BELGIUM, MEXICO, COLOMBIA, IRAN) 54

TABLE 6                NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023 (UK, SPAIN, ARGENTINA, PERU)               54

TABLE 7                NON-SURGICAL PROCEDURES, BY COUNTRY, 2023

(GERMANY, FRANCE, BELGIUM, GREECE)             54

TABLE 8                NON-SURGICAL PROCEDURES, BY COUNTRY, 2023 (US, UK, COLOMBIA, IRAN)                55

TABLE 9                NON-SURGICAL PROCEDURES, BY COUNTRY, 2023

(MEXICO, SPAIN, ARGENTINA, PERU)     55

TABLE 10              AESTHETIC PLASTIC SURGEON FEES IN NORTH AMERICA, 2022 VS. 2023 56

TABLE 11              NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023 57

TABLE 12              NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023 58

TABLE 13              NON-SURGICAL PROCEDURES, BY COUNTRY, 2023        58

TABLE 14              NON-SURGICAL PROCEDURES, BY COUNTRY, 2023        58

TABLE 15              BODY CONTOURING TREATMENTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM    64

TABLE 16              US: MEDICAL DEVICE CLASSIFICATION 65

TABLE 17              US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              65

TABLE 18              US: CLASSIFICATION OF BODY CONTOURING DEVICES              66

TABLE 19              CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS      67

TABLE 20              JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)                 71

TABLE 21              CHINA: CLASSIFICATION OF MEDICAL DEVICES                 72

TABLE 22              REGULATORY APPROVALS FOR BODY CONTOURING DEVICES, BY COUNTRY  74

TABLE 23              NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 74

TABLE 24              EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 75

TABLE 25              ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 76

TABLE 26              LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 76

TABLE 27              MIDDLE EAST & AFRICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             77

TABLE 28              MEDICAL REIMBURSEMENT CODES FOR BODY CONTOURING PROCEDURAL SERVICES IN US, 2023          77

TABLE 29              AVERAGE SELLING PRICE OF KEY PLAYERS, BY TECHNOLOGY, 2024 (USD)          81

TABLE 30              AVERAGE SELLING PRICE OF BODY CONTOURING DEVICES, BY REGION,

2022–2024 (USD)                82

TABLE 31              IMPORT DATA FOR BODY CONTOURING DEVICES (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)      83

TABLE 32              IMPORT DATA FOR LASERS (EXCLUDING LASER DIODES) (HS CODE 901320),

BY COUNTRY, 2019–2023 (USD THOUSAND)         83

TABLE 33              EXPORT DATA FOR BODY CONTOURING DEVICES (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)      84

TABLE 34              EXPORT DATA FOR LASER (EXCLUDING LASER DIODES) (HS CODE 901320),

BY COUNTRY, 2019–2023 (USD THOUSAND)         84

TABLE 35              INNOVATIONS AND PATENT REGISTRATIONS, JANUARY 2021–AUGUST 2024       86

TABLE 36              BODY CONTOURING TREATMENTS MARKET: PORTER’S FIVE FORCES 87

TABLE 37              INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF BODY CONTOURING PRODUCTS 90

TABLE 38              INFLUENCE OF END USERS ON BUYING PROCESS, BY END USER                90

TABLE 39              BODY CONTOURING TREATMENTS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026        91

TABLE 40              BRAND MAPPING OF THERMAL TECHNOLOGIES               94

TABLE 41              BRAND MAPPING OF NON-THERMAL TECHNOLOGIES               95

TABLE 42              BODY CONTOURING TREATMENTS MARKET: CURRENT UNMET NEEDS            97

TABLE 43              BODY CONTOURING TREATMENTS MARKET: INTENSITY OF CURRENT UNMET NEEDS              97

TABLE 44              BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            101

TABLE 45              BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES,

BY TYPE, 2022–2029 (USD MILLION)         102

TABLE 46              BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES,

BY REGION, 2022–2029 (USD MILLION)   102

TABLE 47              BODY CONTOURING TREATMENTS MARKET FOR INVASIVE RADIOFREQUENCY TECHNOLOGY, BY REGION, 2022–2029 (USD MILLION)            103

TABLE 48              BODY CONTOURING TREATMENTS MARKET FOR INVASIVE LASER TECHNOLOGY, BY REGION, 2022–2029 (USD MILLION) 104

TABLE 49              BODY CONTOURING TREATMENTS MARKET FOR INVASIVE ULTRASOUND TECHNOLOGY, BY REGION, 2022–2029 (USD MILLION)       105

TABLE 50              BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)            106

TABLE 51              BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION) 106

TABLE 52              BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE RADIOFREQUENCY TECHNOLOGY, BY REGION, 2022–2029 (USD MILLION)          107

TABLE 53              BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE LASER TECHNOLOGY, BY REGION, 2022–2029 (USD MILLION)       108

TABLE 54              BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE ULTRASOUND TECHNOLOGY, BY REGION, 2022–2029 (USD MILLION)            109

TABLE 55              BODY CONTOURING TREATMENTS MARKET FOR CRYOLIPOLYSIS TECHNOLOGY,

BY REGION, 2022–2029 (USD MILLION)   110

TABLE 56              BODY CONTOURING TREATMENTS MARKET FOR OTHER NON-INVASIVE TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)       111

TABLE 57              BODY CONTOURING TREATMENTS MARKET, BY GENDER,

2022–2029 (USD MILLION)            113

TABLE 58              BODY CONTOURING PROCEDURES IN FEMALE PATIENTS, 2022 VS. 2023                 114

TABLE 59              BODY CONTOURING TREATMENTS MARKET FOR FEMALE PATIENTS, BY REGION, 2022–2029 (USD MILLION)                 114

TABLE 60              BODY CONTOURING PROCEDURES IN MALE PATIENTS, 2022 VS. 2023                 115

TABLE 61              BODY CONTOURING TREATMENTS MARKET FOR MALE PATIENTS, BY REGION, 2022–2029 (USD MILLION)                 116

TABLE 62              BODY CONTOURING TREATMENTS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            118

TABLE 63              TOP 5 COUNTRIES PERFORMING NON-SURGICAL FAT REDUCTION TREATMENTS, 2018–2023    119

TABLE 64              BODY CONTOURING TREATMENTS MARKET FOR NON-SURGICAL FAT REDUCTION, BY REGION, 2022–2029 (USD MILLION) 119

TABLE 65              BODY CONTOURING TREATMENTS MARKET FOR CELLULITE REDUCTION,

BY REGION, 2022–2029 (USD MILLION)   120

TABLE 66              TOP 5 COUNTRIES PERFORMING LIPOSUCTION PROCEDURES, 2018–2023               121

TABLE 67              BODY CONTOURING TREATMENTS MARKET FOR LIPOSUCTION, BY REGION,

2022–2029 (USD MILLION)            121

TABLE 68              TOP 5 COUNTRIES PERFORMING ABDOMINOPLASTY TREATMENTS, 2018–2023     122

TABLE 69              BODY CONTOURING TREATMENTS MARKET FOR ABDOMINOPLASTY, BY REGION, 2022–2029 (USD MILLION)                 122

TABLE 70              BODY CONTOURING TREATMENTS MARKET FOR OTHER APPLICATIONS,

BY REGION, 2022–2029 (USD MILLION)   123

TABLE 71              BODY CONTOURING TREATMENTS MARKET, BY END USER,

2022–2029 (USD MILLION)            125

TABLE 72              BODY CONTOURING TREATMENTS MARKET FOR HOSPITALS, BY REGION,

2022–2029 (USD MILLION)            126

TABLE 73              BODY CONTOURING TREATMENTS MARKET FOR AESTHETIC CLINICS, BY REGION, 2022–2029 (USD MILLION)                 127

TABLE 74              BODY CONTOURING TREATMENTS MARKET FOR MEDICAL SPAS & BEAUTY CENTERS, BY REGION, 2022–2029 (USD MILLION) 128

TABLE 75              BODY CONTOURING TREATMENTS MARKET, BY REGION,

2022–2029 (USD MILLION)            130

TABLE 76              NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)            132

TABLE 77              NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)            132

TABLE 78              NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)         133

TABLE 79              NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)                133

TABLE 80              NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY GENDER,

2022–2029 (USD MILLION)            134

TABLE 81              NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)            134

TABLE 82              NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022–2029 (USD MILLION)            135

TABLE 83              KEY MACROINDICATORS FOR NORTH AMERICA                 135

TABLE 84              US: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            136

TABLE 85              US: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       137

TABLE 86              US: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES,

BY TYPE, 2022–2029 (USD MILLION)         137

TABLE 87              BODY CONTOURING PROCEDURES CONDUCTED IN US, 2020–2023   138

TABLE 88              CANADA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            139

TABLE 89              CANADA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       139

TABLE 90              CANADA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 140

TABLE 91              EUROPE: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            141

TABLE 92              EUROPE: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            141

TABLE 93              EUROPE: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       142

TABLE 94              EUROPE: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 142

TABLE 95              EUROPE: BODY CONTOURING TREATMENTS MARKET, BY GENDER,

2022–2029 (USD MILLION)            143

TABLE 96              EUROPE: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            143

TABLE 97              EUROPE: BODY CONTOURING TREATMENTS MARKET, BY END USER,

2022–2029 (USD MILLION)            144

TABLE 98              KEY MACROINDICATORS FOR EUROPE 145

TABLE 99              BODY CONTOURING PROCEDURES CONDUCTED IN GERMANY, 2020–2023    146

TABLE 100            GERMANY: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            146

TABLE 101            GERMANY: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       146

TABLE 102            GERMANY: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 147

TABLE 103            FRANCE: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            147

TABLE 104            FRANCE: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       148

TABLE 105            FRANCE: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 148

TABLE 107            BODY CONTOURING PROCEDURES CONDUCTED IN UK, 2022–2023   149

TABLE 108            UK: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            150

TABLE 109            UK: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       150

TABLE 110            UK: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES,

BY TYPE, 2022–2029 (USD MILLION)         151

TABLE 111            BODY CONTOURING PROCEDURES CONDUCTED IN ITALY, 2020–2023             151

TABLE 112            ITALY: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            152

TABLE 113            ITALY: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       152

TABLE 114            ITALY: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 153

TABLE 115            BODY CONTOURING PROCEDURES CONDUCTED IN SPAIN, 2021–2023             154

TABLE 116            SPAIN: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            154

TABLE 117            SPAIN: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       154

TABLE 118            SPAIN: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 155

TABLE 119            REST OF EUROPE: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)            155

TABLE 120            REST OF EUROPE: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)         156

TABLE 121            REST OF EUROPE: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)                156

TABLE 122            ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            158

TABLE 123            ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)            158

TABLE 124            ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)         159

TABLE 125            ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)                159

TABLE 126            ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY GENDER,

2022–2029 (USD MILLION)            160

TABLE 127            ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            160

TABLE 128            ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY END USER,

2022–2029 (USD MILLION)            161

TABLE 129            KEY MACROINDICATORS FOR ASIA PACIFIC                 162

TABLE 130            BODY CONTOURING PROCEDURES CONDUCTED IN JAPAN, 2020–2022            163

TABLE 131            JAPAN: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            163

TABLE 132            JAPAN: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       164

TABLE 133            JAPAN: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 164

TABLE 134            CHINA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            165

TABLE 135            CHINA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       166

TABLE 136            CHINA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 166

TABLE 137            BODY CONTOURING PROCEDURES CONDUCTED IN INDIA, 2020–2023             167

TABLE 138            INDIA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            168

TABLE 139            INDIA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       168

TABLE 140            INDIA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 169

TABLE 141            AUSTRALIA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            170

TABLE 142            AUSTRALIA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)         170

TABLE 143            AUSTRALIA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)                171

TABLE 144            SOUTH KOREA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)            172

TABLE 145            SOUTH KOREA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)         172

TABLE 146            SOUTH KOREA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)                173

TABLE 147            REST OF ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     173

TABLE 148            REST OF ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR

NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)            174

TABLE 149            REST OF ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)                174

TABLE 150            LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            175

TABLE 151            LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)            175

TABLE 152            LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)         176

TABLE 153            LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)                176

TABLE 154            LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY GENDER,

2022–2029 (USD MILLION)            177

TABLE 155            LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)            177

TABLE 156            LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY END USER,

2022–2029 (USD MILLION)            178

TABLE 157            KEY MACROINDICATORS FOR LATIN AMERICA                 179

TABLE 158            BODY CONTOURING PROCEDURES CONDUCTED IN BRAZIL, 2020–2023          180

TABLE 159            BRAZIL: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            180

TABLE 160            BRAZIL: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       180

TABLE 161            BRAZIL: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 181

TABLE 162            MEXICO: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            182

TABLE 163            MEXICO: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)       182

TABLE 164            MEXICO: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 183

TABLE 165            BODY CONTOURING PROCEDURES CONDUCTED IN ARGENTINA, 2020–2023                184

TABLE 166            REST OF LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     184

TABLE 167            REST OF LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR

NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)            184

TABLE 168            REST OF LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)                185

TABLE 169            MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)            186

TABLE 170            MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     186

TABLE 171            MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET FOR

NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)            187

TABLE 172            MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)                187

TABLE 173            MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET,

BY GENDER, 2022–2029 (USD MILLION)  188

TABLE 174            MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)       188

TABLE 175            MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET,

BY END USER, 2022–2029 (USD MILLION)               189

TABLE 176            KEY MACROINDICATORS FOR MIDDLE EAST & AFRICA 190

TABLE 177            OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BODY CONTOURING TREATMENTS MARKET                 191

TABLE 178            BODY CONTOURING TREATMENTS MARKET: DEGREE OF COMPETITION         195

TABLE 179            BODY CONTOURING TREATMENTS MARKET: TECHNOLOGY FOOTPRINT        200

TABLE 180            BODY CONTOURING TREATMENTS MARKET: GENDER FOOTPRINT    201

TABLE 181            BODY CONTOURING TREATMENTS MARKET: APPLICATION FOOTPRINT         202

TABLE 182            BODY CONTOURING TREATMENTS MARKET: END-USER FOOTPRINT 203

TABLE 183            BODY CONTOURING TREATMENTS MARKET: REGION FOOTPRINT     204

TABLE 184            BODY CONTOURING TREATMENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES             207

TABLE 185            BODY CONTOURING TREATMENTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES    208

TABLE 186            BODY CONTOURING TREATMENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–AUGUST 2024     211

TABLE 187            BODY CONTOURING TREATMENTS MARKET: DEALS, JANUARY 2021–

AUGUST 2024     213

TABLE 188            BODY CONTOURING TREATMENTS MARKET: EXPANSIONS, JANUARY 2021–AUGUST 2024          214

TABLE 189            ABBVIE INC.: COMPANY OVERVIEW        215

TABLE 190            ABBVIE INC.: PRODUCTS OFFERED         216

TABLE 191            ABBVIE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−

AUGUST 2024     217

TABLE 192            INMODE LTD.: COMPANY OVERVIEW    218

TABLE 193            INMODE LTD.: PRODUCTS OFFERED     219

TABLE 194            INMODE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−

AUGUST 2024     220

TABLE 195            INMODE LTD.: DEALS, JANUARY 2021− AUGUST 2024        221

TABLE 196            BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW          222

TABLE 197            BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED             223

TABLE 198            BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−AUGUST 2024                 224

TABLE 199            CYNOSURE LUTRONIC: COMPANY OVERVIEW                 225

TABLE 200            CYNOSURE LUTRONIC: PRODUCTS OFFERED                 225

TABLE 201            CYNOSURE LUTRONIC: DEALS, JANUARY 2021−AUGUST 2024         226

TABLE 202            SISRAM MEDICAL LTD: COMPANY OVERVIEW                 227

TABLE 203            SISRAM MEDICAL LTD: PRODUCTS OFFERED                 228

TABLE 204            SISRAM MEDICAL LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021− AUGUST 2024               229

TABLE 205            SISRAM MEDICAL LTD: DEALS, JANUARY 2021−AUGUST 2024         229

TABLE 206            SISRAM MEDICAL LTD: EXPANSIONS, JANUARY 2021−AUGUST 2024         230

TABLE 207            CUTERA, INC.: COMPANY OVERVIEW     231

TABLE 208            CUTERA, INC.: PRODUCTS OFFERED      232

TABLE 209            CUTERA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−

AUGUST 2024     233

TABLE 210            EL.EN. S.P.A.: COMPANY OVERVIEW        234

TABLE 211            EL.EN. S.P.A.: PRODUCTS OFFERED         235

TABLE 212            EL.EN. S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−

AUGUST 2024     236

TABLE 213            VENUS CONCEPT: COMPANY OVERVIEW                 237

TABLE 214            VENUS CONCEPT: PRODUCTS OFFERED                 238

TABLE 215            VENUS CONCEPT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−

AUGUST 2024     239

TABLE 216            VENUS CONCEPT: DEALS, JANUARY 2021−AUGUST 2024         240

TABLE 217            SHARPLIGHT TECHNOLOGIES INC.: COMPANY OVERVIEW          241

TABLE 218            SHARPLIGHT TECHNOLOGIES INC.: PRODUCTS OFFERED             241

TABLE 219            SHARPLIGHT TECHNOLOGIES INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−AUGUST 2024                 242

TABLE 220            SCITON: COMPANY OVERVIEW 243

TABLE 221            SCITON: PRODUCTS OFFERED  243

TABLE 222            SCITON: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−AUGUST 2024          243

TABLE 223            CANDELA CORPORATION: COMPANY OVERVIEW          244

TABLE 224            CANDELA CORPORATION: PRODUCTS OFFERED             244

TABLE 225            CANDELA CORPORATION: DEALS, JANUARY 2021−AUGUST 2024         244

TABLE 226            BTL INDUSTRIES: COMPANY OVERVIEW                 245

TABLE 227            BTL INDUSTRIES: PRODUCTS OFFERED                 245

TABLE 228            BTL INDUSTRIES: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−

AUGUST 2024     246

TABLE 229            BTL INDUSTRIES: DEALS, JANUARY 2021−AUGUST 2024         246

TABLE 230            FOTONA: COMPANY OVERVIEW               247

TABLE 231            FOTONA: PRODUCTS OFFERED                247

TABLE 232            FOTONA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−AUGUST 2024          248

TABLE 233            GZ MTS ELECTRONICS CO., LTD.: COMPANY OVERVIEW          249

TABLE 234            GZ MTS ELECTRONICS CO., LTD.: PRODUCTS OFFERED             249

TABLE 235            ROHRER AESTHETICS, INC.: COMPANY OVERVIEW          252

TABLE 236            ROHRER AESTHETICS, INC.: PRODUCTS OFFERED             252

TABLE 237            ROHRER AESTHETICS, INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021−AUGUST 2024     253

TABLE 238            ROHRER AESTHETICS, INC.: DEALS, JANUARY 2021−AUGUST 2024         253

TABLE 239            GBS INTERNATIONAL HOLDING LTD.: COMPANY OVERVIEW   254

TABLE 240            SINCLAIR: COMPANY OVERVIEW              255

TABLE 241            THERMI: COMPANY OVERVIEW 256

TABLE 242            YOLO MEDICAL INC.: COMPANY OVERVIEW                 256

TABLE 243            DOMINION AESTHETIC TECHNOLOGIES, INC.: COMPANY OVERVIEW   257

TABLE 244            ZIMMER MEDIZINSYSTEME GMBH: COMPANY OVERVIEW          258

TABLE 245            ERCHONIA CORPORATION: COMPANY OVERVIEW          259

TABLE 246            CLASSYS INC.: COMPANY OVERVIEW      260

TABLE 247            WON TECH CO., LTD.: COMPANY OVERVIEW                 261

TABLE 248            CELLSOUND AESTHETICS: COMPANY OVERVIEW          262

LIST OF FIGURES

FIGURE 1              BODY CONTOURING TREATMENTS MARKET SEGMENTATION              28

FIGURE 2              BODY CONTOURING TREATMENTS MARKET: RESEARCH DESIGN         30

FIGURE 3              BODY CONTOURING TREATMENTS MARKET: KEY PRIMARY SOURCES

(DEMAND- AND SUPPLY-SIDE PARTICIPANTS) 32

FIGURE 4              BODY CONTOURING TREATMENTS: KEY INSIGHTS FROM PRIMARY INTERVIEWS                33

FIGURE 5              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS     33

FIGURE 6              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,

AND REGION     34

FIGURE 7              RESEARCH METHODOLOGY: HYPOTHESIS BUILDING           35

FIGURE 8              BODY CONTOURING TREATMENTS MARKET SIZE ESTIMATION:

COMPANY REVENUE ESTIMATION          36

FIGURE 9              BODY CONTOURING TREATMENTS MARKET SIZE ESTIMATION:

BOTTOM-UP APPROACH              37

FIGURE 10            CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 38

FIGURE 11            DATA TRIANGULATION METHODOLOGY                 39

FIGURE 12            BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY,

2024 VS. 2029 (USD MILLION)      42

FIGURE 13            BODY CONTOURING TREATMENTS MARKET, BY GENDER,

2024 VS. 2029 (USD MILLION)      43

FIGURE 14            BODY CONTOURING TREATMENTS MARKET, BY APPLICATION,

2024 VS. 2029 (USD MILLION)      43

FIGURE 15            BODY CONTOURING TREATMENTS MARKET, BY END USER,

2024 VS. 2029 (USD MILLION)      44

FIGURE 16            BODY CONTOURING TREATMENTS MARKET, BY REGION, 2024–2029 (CAGR)    45

FIGURE 17            GROWING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES TO DRIVE MARKET 46

FIGURE 18            NON-INVASIVE TECHNOLOGIES SEGMENT TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD                 47

FIGURE 19            AESTHETIC CLINICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD    47

FIGURE 20            ABDOMINOPLASTY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD    48

FIGURE 21            CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD       49

FIGURE 22            BODY CONTOURING TREATMENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                 50

FIGURE 23            NON-SURGICAL PROCEDURES PERFORMED GLOBALLY, 2023 VS. 2022               51

FIGURE 24            BODY CONTOURING TREATMENTS MARKET: VALUE CHAIN ANALYSIS               60

FIGURE 25            BODY CONTOURING TREATMENTS MARKET: SUPPLY CHAIN ANALYSIS             62

FIGURE 26            BODY CONTOURING TREATMENTS MARKET: ECOSYSTEM ANALYSIS  63

FIGURE 27            PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES      66

FIGURE 28            CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES                68

FIGURE 29            EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES              70

FIGURE 30            INVESTMENT AND FUNDING SCENARIO IN BODY CONTOURING TREATMENTS MARKET, 2019−2023 (USD MILLION)            78

FIGURE 31            NUMBER OF INVESTOR DEALS IN BODY CONTOURING TREATMENTS MARKET,

BY KEY PLAYER, 2019−2023 (UNIT)          79

FIGURE 32            VALUE OF INVESTOR DEALS IN BODY CONTOURING TREATMENTS MARKET,

BY KEY PLAYER, 2018–2022 (USD MILLION)           79

FIGURE 33            AVERAGE SELLING PRICE OF KEY PLAYERS, BY TECHNOLOGY, 2024        80

FIGURE 34            AVERAGE SELLING PRICE OF BODY CONTOURING DEVICES, BY REGION, 2024            81

FIGURE 35            BODY CONTOURING TREATMENTS MARKET: PATENT ANALYSIS, 2014–2024     85

FIGURE 36            BODY CONTOURING TREATMENTS MARKET: PORTER’S FIVE FORCES ANALYSIS           87

FIGURE 37            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BODY CONTOURING PRODUCTS  89

FIGURE 38            KEY BUYING CRITERIA, BY END USER    91

FIGURE 39            NEW REVENUE POCKETS FOR PLAYERS IN BODY CONTOURING

TREATMENTS MARKET 96

FIGURE 40            MARKET POTENTIAL OF AI/GENERATIVE AI ON BODY CONTOURING

TREATMENTS MARKET 98

FIGURE 41            NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET SNAPSHOT         131

FIGURE 42            ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET SNAPSHOT         157

FIGURE 43            REVENUE ANALYSIS OF TOP PLAYERS IN BODY CONTOURING TREATMENTS MARKET, 2019−2023           194

FIGURE 44            MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023        195

FIGURE 45            RANKING OF KEY PLAYERS IN BODY CONTOURING TREATMENTS MARKET, 2023        196

FIGURE 46            BODY CONTOURING TREATMENTS MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023       198

FIGURE 47            BODY CONTOURING TREATMENTS MARKET: COMPANY FOOTPRINT 199

FIGURE 48            BODY CONTOURING TREATMENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023                 206

FIGURE 49            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA

OF KEY VENDORS            209

FIGURE 50            EV/EBITDA OF KEY VENDORS   209

FIGURE 51            BODY CONTOURING TREATMENTS MARKET: BRAND/PRODUCT COMPARISON             210

FIGURE 52            ABBVIE INC.: COMPANY SNAPSHOT (2023)                 216

FIGURE 53            INMODE LTD.: COMPANY SNAPSHOT (2023)                 219

FIGURE 54            BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2023)             223

FIGURE 55            SISRAM MEDICAL LTD: COMPANY SNAPSHOT (2023)    228

FIGURE 56            CUTERA, INC.: COMPANY SNAPSHOT (2023)                 232

FIGURE 57            EL.EN. S.P.A.: COMPANY SNAPSHOT (2023)                 235

FIGURE 58            VENUS CONCEPT: COMPANY SNAPSHOT (2023)                 238

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧